ライフサイエンスコーパス: nicotine patch

1 occasions, in the presence and absence of a nicotine patch.

2 curred in 1993 after the introduction of the nicotine patch.

3 rse event rates between e-cigarettes and the nicotine patch.

4 be as effective for smoking cessation as the nicotine patch.

5 utcomes for smoking cessation treatment with nicotine patch.

6 Single-dose (21- or 35-mg) nicotine patch.

7 eutical company could market its transdermal nicotine patch.

8 human smokers or in users of the transdermal nicotine patch.

9 human smokers or in users of the transdermal nicotine patch.

10 nd in smokers or in users of the transdermal nicotine patch.

11 g (12.6 +/- 10.1%) and 21-mg (11.8 +/- 9.9%) nicotine patches.

12 king and during treatment with 14- and 21-mg nicotine patches.

13 ine and during treatment with at least 14-mg nicotine patches.

14 ents with ADNFLE who use tobacco products or nicotine patches.

15 (odds ratio [OR] 3.61, 95% CI 3.07 to 4.24), nicotine patch (1.68, 1.46 to 1.93), and bupropion (1.75

16 245 of 2006 participants]), abnormal dreams (nicotine patch, 12% [251 of 2022 participants]), and hea

17 Adding a nicotine patch (15 mg per 16 hours) to behavioral cessat

18 assigned to 8 weeks of treatment with active nicotine patches (15 mg per 16 hours) or matched placebo

19 l-free quitline were sent a 6-week course of nicotine patches (2 weeks each of 21 mg, 14 mg, and 7 mg

20 and C-NRT, 26.8% [113/421]) or at 52 weeks (nicotine patch, 20.8% [50/241]; varenicline, 19.1% [81/4

21 t fast event-related fMRI twice: once with a nicotine patch (21 mg) and once with a placebo patch.

22 y, placebo-controlled and active-controlled (nicotine patch; 21 mg per day with taper) trial of varen

23 ing point-prevalence abstinence at 26 weeks (nicotine patch, 22.8% [55/241]; varenicline, 23.6% [100/

24 ustained-release bupropion (244 subjects), a nicotine patch (244 subjects), bupropion and a nicotine

25 cotine patch (244 subjects), bupropion and a nicotine patch (245 subjects), and placebo (160 subjects

26 to the three interventions (408 placebo, 418 nicotine patch, 420 varenicline).

27 e patch+denicotinized cigarette smoking, (2) nicotine patch+abstinence from smoking, (3) placebo patc

28 Those on bupropion and nicotine patch achieved higher abstinence rates than tho

29 f placebo (placebo pill plus placebo patch), nicotine patch (active patch plus placebo pill), or vare

30 ers and control subjects, implies that acute nicotine patch administration is insufficient to modify

31 triatal circuits, which were not modified by nicotine patch administration.

32 ned to one of three double-blind treatments: nicotine patch alone (control condition); "rescue" treat

33 ence rates at end of treatment were 16% with nicotine patch alone and 28% with bupropion augmentation

34 have failed to achieve abstinence if left on nicotine patch alone by identifying these smokers before

35 blocked randomization to receive either the nicotine patch alone for a standard 10-week, tapering co

36 of smoking cessation than use of either the nicotine patch alone or placebo.

37 assigned to the two rescue treatments or to nicotine patch alone.

38 d efficacy of varenicline and bupropion with nicotine patch and placebo in smokers with and without p

39 omised, placebo-controlled efficacy trial of nicotine patches and a survey of associated resource use

40 There was no association between nicotine patches and MI (OR 0.46; 95% CI: 0.09, 1.47), a

41 on physician time and the retail cost of the nicotine patch, and benefits were based on quality-adjus

42 Varenicline was more effective than placebo, nicotine patch, and bupropion in helping smokers achieve

43 easons and cessation treatments, such as the nicotine patch, are preferentially beneficial to men.

44 For most of the subjects who used the nicotine patch as a smoking cessation aid, urinary total

45 involving more intensive counseling and the nicotine patch as adjuvant therapy are particularly meri

46 vide support both for the routine use of the nicotine patch as an adjunct to physicians' smoking cess

47 Nicotine patches, as used in actual practice, do not app

48 o did not respond adequately to precessation nicotine patch benefited from bupropion augmentation; ab

49 The incremental cost-effectiveness of the nicotine patch by age group ranged from $4390 to $10 943

50 Each subject (12) received placebo and nicotine patches combined with one of the stimulation pr

51 with varenicline and slow metabolisers with nicotine patch could optimise quit rates while minimisin

52 29 adult smokers across four conditions: (1) nicotine patch+denicotinized cigarette smoking, (2) nico

53 We investigated the efficacy and safety of nicotine patches during pregnancy.

54 idence interval (CI) excluded an effect from nicotine patches equal to that from cigarette smoking it

55 l subjects received 8 weeks of a transdermal nicotine patch, five group counseling sessions, and acti

56 ed more frequent adverse events than did the nicotine patch for vivid dreams, insomnia, nausea, const

57 HS, of allowing GPs to prescribe transdermal nicotine patches for up to 12 weeks.

58 he bupropion group, 25 (2.5%) of 1006 in the nicotine patch group, and 24 (2.4%) of 999 in the placeb

59 he bupropion group, 53 (5.2%) of 1016 in the nicotine patch group, and 50 (4.9%) of 1015 in the place

60 n the placebo group (3.8 percent), 16 in the nicotine-patch group (6.6 percent), 29 in the bupropion

61 group, as compared with 16.4 percent in the nicotine-patch group, 30.3 percent in the bupropion grou

62 kg, as compared with a gain of 1.6 kg in the nicotine-patch group, a gain of 1.7 kg in the bupropion

63 Although nicotine patches improve smoking cessation rates, case r

64 tment, varenicline was more efficacious than nicotine patch in normal metabolisers (OR 2.17, 95% CI 1

65 g Philadelphia was performed to determine if nicotine patches increase the risk of first MI.

66 Their efficacy relative to nicotine patch largely relies on indirect comparisons, a

67 sation clinical trials and were treated with nicotine patch (n=623), nicotine nasal spray (n=189), bu

68 ing 1 prequit week; n = 424); and (3) C-NRT (nicotine patch + nicotine lozenge; n = 421).

69 pering course (n = 64) or the combination of nicotine patch, nicotine oral inhaler, and bupropion ad

70 There was no effect of the nicotine patch on levels of NNAL plus NNAL-Gluc, indicat

71 If GPs were allowed to prescribe transdermal nicotine patches on the NHS, for up to 12 weeks, the inc

72 moking cessation pharmacotherapy groups: (1) nicotine patch only (n = 241); (2) varenicline only (inc

73 able to varenicline or bupropion relative to nicotine patch or placebo.

74 roxycotinine:cotinine), predicts response to nicotine patch or varenicline for smoking cessation.

75 ated by quitting cigarettes and switching to nicotine patches or by antioxidant vitamin therapy.

76 percent in the group given bupropion and the nicotine patch (P<0.001).

77 ith those reported in previous research, the nicotine patch plus lozenge produced the greatest benefi

78 With such protection, only the nicotine patch plus nicotine lozenge (odds ratio, 2.34,

79 nicotine patch, sustained-release bupropion, nicotine patch plus nicotine lozenge, bupropion plus nic

80 ble-blind, placebo-controlled treatment with nicotine patch (random assignment).

81 ase bupropion alone or in combination with a nicotine patch resulted in significantly higher long-ter

82 Thirteen used the nicotine patch starting at the quit date, whereas the ot

83 Nicotine patches substantially increase quit rates among

84 he effect of smoking cessation (3 weeks) and nicotine patch supplementation, (4) the effect of aspiri

85 of 6 treatment conditions: nicotine lozenge, nicotine patch, sustained-release bupropion, nicotine pa

86 dult smokers from the general population for nicotine patch therapy and based the patch dosage on smo

87 hs was more effective than standard-duration nicotine patch therapy for outpatient smokers with medic

88 Tailored nicotine patch therapy for the general population of smo

89 Of those subjects not smoking at the end of nicotine patch therapy who entered the relapse preventio

90 For those still smoking at the end of nicotine patch therapy, 3.1% and 0.0% stopped smoking wi

91 At completion of nicotine patch therapy, nonsmoking participants were eli

92 We sought to determine the effects of nicotine patch therapy, when used to promote smoking ces

93 nseling and for health insurance coverage of nicotine patch therapy.

94 1% were abstinent from smoking at the end of nicotine patch therapy.

95 smoking in smokers who stopped smoking with nicotine patch therapy.

96 mong smokers who failed to stop smoking with nicotine patch therapy.

97 daily) or placebo, as well as eight weeks of nicotine-patch therapy (21 mg per day during weeks 2 thr

98 Addition of the nicotine patch to physician-based smoking cessation coun

99 of 606 cigarette smokers started open-label nicotine patch treatment 2 weeks before the quit date.

100 moking cessation treatment strategy in which nicotine patch treatment was initiated before a quit dat

101 how a sufficient initial response to prequit nicotine patch treatment, combination treatment with var

102 deemed unlikely to achieve abstinence using nicotine patch treatment.

103 of more than 50% in smoking after 1 week of nicotine patch treatment.

104 We calculated the health benefit of nicotine-patch treatment in number of life years that wo

105 t per life year saved by GP counselling with nicotine-patch treatment over GP counselling alone.

106 tween cigarette smoking or vaping, or during nicotine patch use.

107 oking, 12 weeks of open-label treatment with nicotine patch, varenicline, or C-NRT produced no signif

108 on initial therapeutic response, either the nicotine patch was continued or alternative pharmacother

109 ho abstained from smoking, the OR for use of nicotine patches was 0.25 (95% CI: 0.01, 1.67); among th

110 , respectively; the RDs for comparisons with nicotine patch were -1.07 (-2.21 to 0.08) and 0.13 (-1.1

111 -0.24 to 3.81), respectively; the RDs versus nicotine patch were 1.22 (-0.81 to 3.25) and 1.42 (-0.63

112 Behavioral counseling and open-label nicotine patch were also included for the first 4-6 week

113 rs achieve abstinence, whereas bupropion and nicotine patch were more effective than placebo.

114 Nicotine patches, when used to promote smoking cessation

115 way to use NRT is to combine the long-acting nicotine patch with a shorter-acting product (lozenge, g